Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram.

Kutikov A, Cooperberg MR, Paciorek AT, Uzzo RG, Carroll PR, Boorjian SA.

Prostate Cancer Prostatic Dis. 2012 Dec;15(4):374-9. doi: 10.1038/pcan.2012.21. Epub 2012 Jun 19.

2.

Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.

Lee BH, Kibel AS, Ciezki JP, Klein EA, Reddy CA, Yu C, Kattan MW, Stephenson AJ.

Eur Urol. 2015 Feb;67(2):204-9. doi: 10.1016/j.eururo.2014.09.017. Epub 2014 Oct 5.

PMID:
25294696
3.

Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group.

Teeter AE, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ.

Urology. 2013 Jul;82(1):53-8. doi: 10.1016/j.urology.2012.10.090.

5.

Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.

Aizer AA, Chen MH, Hattangadi J, D'Amico AV.

BJU Int. 2014 Jan;113(1):43-50. doi: 10.1111/j.1464-410X.2012.11789.x. Epub 2013 Mar 8.

6.

Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.

Cooperberg MR, Broering JM, Carroll PR.

J Natl Cancer Inst. 2009 Jun 16;101(12):878-87. doi: 10.1093/jnci/djp122. Epub 2009 Jun 9.

7.

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.

Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.

J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24. Epub 2007 Oct 9.

PMID:
17925537
8.

Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.

Cooperberg MR, Vickers AJ, Broering JM, Carroll PR.

Cancer. 2010 Nov 15;116(22):5226-34. doi: 10.1002/cncr.25456. Erratum in: Cancer. 2011 Jun 15;117(12):2825.

9.

Impact of surgical margin status on prostate-cancer-specific mortality.

Chalfin HJ, Dinizo M, Trock BJ, Feng Z, Partin AW, Walsh PC, Humphreys E, Han M.

BJU Int. 2012 Dec;110(11):1684-9. doi: 10.1111/j.1464-410X.2012.11371.x. Epub 2012 Jul 12.

11.

Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV.

J Clin Oncol. 2005 Oct 1;23(28):6992-8.

PMID:
16192586
12.

Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr, Yossepowitch O, Vickers AJ, Klein EA, Wood DP, Scardino PT.

J Clin Oncol. 2009 Sep 10;27(26):4300-5. doi: 10.1200/JCO.2008.18.2501. Epub 2009 Jul 27.

13.

Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.

Gnanapragasam VJ, Lophatananon A, Wright KA, Muir KR, Gavin A, Greenberg DC.

PLoS Med. 2016 Aug 2;13(8):e1002063. doi: 10.1371/journal.pmed.1002063. eCollection 2016 Aug.

14.

Short-course androgen deprivation therapy and the risk of death from high-risk prostate cancer in men undergoing external beam radiation therapy and brachytherapy.

Raldow AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV.

Brachytherapy. 2015 Nov-Dec;14(6):781-7. doi: 10.1016/j.brachy.2015.08.004. Epub 2015 Sep 9.

PMID:
26361718
15.

Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1).

Schymura MJ, Kahn AR, German RR, Hsieh MC, Cress RD, Finch JL, Fulton JP, Shen T, Stuckart E.

BMC Cancer. 2010 Apr 19;10:152. doi: 10.1186/1471-2407-10-152.

16.

Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.

Tendulkar RD, Hunter GK, Reddy CA, Stephans KL, Ciezki JP, Abdel-Wahab M, Stephenson AJ, Klein EA, Mahadevan A, Kupelian PA.

Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):94-9. doi: 10.1016/j.ijrobp.2013.05.044.

PMID:
23920389
17.
18.

Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging.

Muralidhar V, Dinh KT, Mahal BA, Ziehr DR, Chen YW, Viswanathan VB, Nezolosky MD, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Trinh QD, Nguyen PL.

Urol Oncol. 2015 Jul;33(7):330.e19-25. doi: 10.1016/j.urolonc.2015.03.010. Epub 2015 May 16.

PMID:
25990612
19.

Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer.

Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Hoffman KE, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL.

Clin Genitourin Cancer. 2014 Oct;12(5):e189-95. doi: 10.1016/j.clgc.2014.04.003. Epub 2014 May 9.

PMID:
24861952

Supplemental Content

Support Center